Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy.

Memorial Sloan-Kettering Cancer Center, New York, NY, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:New York, NY
Treatments:ChemotherapyHospital:Memorial Sloan-Kettering Cancer Center
Drugs:Journal:Link
Date:Jun 2012

Description:

Patients:
This phase 3 study involved platinum-sensitive recurrent ovarian, primary peritoneal, or fallopian tube cancer patients who had received prior platinum-based chemotherapy. Patients were divided into two separate treatment groups. Group A had 242 patients with a median age of 61 years, while group B had 242 patients with a median age of 60 years.

Treatment:
Patients in group A were treated with the chemotherapy agents gemcitabine and carboplatin.

Patients in group B were treated with the biologic therapy agent bevacizumab and the chemotherapy agents gemcitabine and carboplatin.

Toxicities:
One treatment-related death due to heart attack was reported for group A. Grade 4 neutropenia was also reported.

One adverse event-related death due to brain hemorrhage was reported for group B. Grade 4 neutropenia and grade 3-4 high blood pressure were also reported.

Results:
The median overall survival times for groups A and B were 35.2 and 33.3 months, respectively.

Support:
This study was supported by Genentech.

Correspondence: Dr. Carol Aghajanian; email: aghajanc@mskcc.org



Back